drugset / Trial / NCT01107054

A Study to Investigate the Effects of PF00610335 on the QT/QTC Interval in Healthy Volunteers

NCT01107054

Phase 1 Completed 48 enrolled Pfizer
RandomizedCrossoverDouble-blindTreatment

Summary

A study to determine the cardiovascular effects of PF00610335 in healthy volunteers.

Timeline

Start
2010-06
Primary completion
2010-09
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Moxifloxacin Small molecule 400 mg Oral
Subject PF-00610355 Small molecule 450 ug Inhaled
Subject PF-00610355 Small molecule 1200 ug Inhaled

Indications